Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | CTSC | P53634 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2917309 | 1.00 | POLB (0.41) | POLBNR3C1CTSLCTSSCTSK | |
| SCHEMBL5790692 | 1.00 | POLB (0.41) | POLBNR3C1CTSLCTSSCTSK | |
| SCHEMBL7372550 | 0.85 | MEN1 (0.41) | CTSLCTSSCTSKPTGES2TAAR1 | |
| SCHEMBL7085022 | 0.81 | CA1 (0.49) | CTSCMEN1KMT2ACA2 | |
| SCHEMBL4541620 | 0.79 | CA2 (0.61) | POLBCTSLCTSSCTSKMEN1 | |
| SCHEMBL4541622 | 0.79 | CA2 (0.61) | POLBCTSLCTSSCTSKMEN1 | |
| SCHEMBL1310109 | 0.78 | TAAR1 (0.53) | TAAR1SLC18A2SIGMAR1CTSCMEN1 | |
| SCHEMBL6852331 | 0.78 | TAAR1 (0.53) | TAAR1SLC18A2SIGMAR1CTSCMEN1 | |
| SCHEMBL1086155 | 0.78 | TAAR1 (0.53) | TAAR1SLC18A2SIGMAR1CTSCMEN1 | |
| SCHEMBL12204083 | 0.77 | SIGMAR1 (0.57) | TAAR1SLC18A2SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481709-B2 | Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism | OBE THERAPY BIOTECHNOLOGY (FR) | 2016-11-01 | — | — | US | disclosed |
| US-20140187479-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | OBE THERAPY BIOTECHNOLOGY (FR) | 2014-07-03 | — | — | US | disclosed |
| US-20100311690-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | OBE THERAPY BIOTECHNOLOGY (FR) | 2010-12-09 | — | — | US | disclosed |
| EP-2225261-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | OBE THERAPY BIOTECHNOLOGY (FR) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009071601-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | OBE THERAPY BIOTECHNOLOGY (FR) | 2009-06-11 | — | — | WO | disclosed |
| US-5484772-A | ARGININE ALDEHYDE COMPOUNDS AS ANTICOAGULANTS OR TREATMENT OF THROMBOEMBOLITIC AGENTS | ELI LILLY AND COMPANY (US) | 1996-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311690-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | TMPRSS15, PCSK9, ANPEP | POLB 4180/4885NR3C1 3526/4885CTSL 566/4885 |
| US-20140187479-A1 | BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM | TMPRSS15, PCSK9, FABP4 | POLB 3892/4885NR3C1 3147/4885CTSL 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.